- Myriad Genetics (MYGN +8.1%) has settled a patent suit against fellow diagnostic testing firm Gene by Gene. As part of the deal, Gene by Gene will stop selling diagnostic tests in North America (but not elsewhere) that "include analysis of the BRCA1 and/or BRCA2 genes as a standalone test or in conjunction with gene panels."
- Gene by Gene will continue selling its whole genome/exome products in North America, as well as "custom array products that test variants for inherited Mendelian disorders."
- Myriad has sued a slew of companies for allegedly infringing its BRCA1/BRCA2 gene testing IP.
- Shares are adding to the gains it saw earlier this week in response to its FQ2 beat and the Crescendo Biosciences acquisition. Helping Myriad's cause: Credit Suisse has belatedly upgraded shares to Neutral.
From other sites
at Zacks.com (Mar 9, 2015)
at Zacks.com (Mar 2, 2015)
at Benzinga.com (Feb 25, 2015)
at Nasdaq.com (Feb 12, 2015)
at Nasdaq.com (Jan 29, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs